Vincristine-ticlopidine-aspirin: An effective therapy in children with Kasabach-Merritt phenomenon associated with vascular tumors

Pediatric Hematology and Oncology

Volumn 27, Issue 8, 2010, Pages 641-645

  Fernandez Pineda, Israel ^a   Lopez Gutierrez, Juan Carlos ^b   Ramirez, Gema ^a   Marquez, Catalina ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL INFANTIL LA PAZ   (Spain)

Author keywords

Aspirin; Kasabach Merritt phenomenon; Ticlopidine; Vascular tumors; Vincristine

Indexed keywords

ACETYLSALICYLIC ACID; D DIMER; FIBRINOGEN; PREDNISOLONE; TICLOPIDINE; VINCRISTINE;

ANEMIA; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD VESSEL; CASE REPORT; CHEEK; CORTICOSTEROID THERAPY; DOPPLER ECHOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPOFIBRINOGENEMIA; INFANT; KAPOSIFORM HEMANGIOTHELIOMA; KASABACH MERRITT SYNDROME; MAGNETIC RESONANCE ANGIOGRAPHY; MUSCLE; NECK; NERVE; PROTEIN BLOOD LEVEL; SKIN BIOPSY; SKIN DEFECT; SKIN EXAMINATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TUFTED ANGIOMA; TUMOR VOLUME; VASCULAR TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPIRIN; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEMANGIOMA, CAPILLARY; HUMANS; INFANT; TICLOPIDINE; TREATMENT OUTCOME; VASCULAR NEOPLASMS; VINCRISTINE;

EID: 77958040805     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2010.508299     Document Type: Article

References (12)

1. Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child. 1940;59:1063-1070.
2. Tsang WYW, Chan JKC. Kaposi-like infantile hemangioendothelioma: a distinctive vascular neoplasm of the retroperitoneum. Am J Surg Pathol. 1991;15:982-989.
3. Mulliken JB, Boon LM, Takahashi K, et al. Pharmacologic therapy for endangering hemangiomas. Curr Opin Dermatol. 1995;2:109-113.
4. SarkarM,Mulliken JB, Kozakewich HPW, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg. 1997;100:1377-1386.
5. Chu CY, Hsiao CH, Chiu HC. Transformation between kaposiform hemangioendothelioma and tufted angioma. Dermatology. 2003;206:334-337.
6. Arai E, Kuramochi A, Tsuchida T, et al. Usefulness of D2-40 immunohistochemistry for differentiation between kaposiform hemangioendothelioma and tufted angioma. J Cutan Pathol. 2006;33:492-497.
7. Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol. 2000;42:225-235.
8. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456-1463.
9. Adams D, Haisley-Royster CA, Enjolras O, et al. Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol. 2002;24:459-462.
10. Koerper MA, Addiego JA, de Lorimier AA, et al. Use of aspirin and dipyridamole in children with platelet trapping syndromes. J Pediatr. 1983;102:311-314.
11. Moimeaux V, Taieb A, Legrain V, et al. Aspirin-ticlopidine in Kasabach-Merritt syndrome. Lancet. 1992;340:55.
12. Ĺopez Gutíerrez JC, Patŕon Romero M. Thoracic kaposiform hemangioendothelioma. Four consecutive cases with distinct outcome. Ann Pediatr. 2005;63:72-76.